MedTrace Logo

A Study of WVT078 in Patients With Multiple Myeloma (MM)

NCT04123418 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-12-24

No results posted yet for this study

Summary

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

Conditions

  • Multiple Myeloma (MM)

Interventions

BIOLOGICAL

WVT078

WVT078 will be administered IV (intravenously) in a dose escalation schedule

DRUG

WHG626

WHG626 will be administered orally in a dose escalation schedule

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2024-12-02
Completion
2024-12-02
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Israel
  • Italy
  • Japan
  • Norway
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04123418 on ClinicalTrials.gov